Hemodialysis Management of Anemia in Chronic Kidney Disease

Pathophysiology of CKD Anemia

  • Erythropoietin (EPO) deficiency (peritubular fibroblast loss)
  • Iron restriction (hepcidin-mediated blockade of absorption/mobilization)
  • Uremic toxin suppression of erythropoiesis
  • Blood loss (dialysis circuit, lab draws, GI angiodysplasia)
  • Folate/B12 deficiency (dialysis loss, poor intake)

How Hemodialysis Addresses Each

  1. EPO Stimulation: Uremic clearance improves residual renal EPO; but most still need ESA therapy (epoetin, darbepoetin).
  2. Iron Repletion: IV iron (sucrose, gluconate, ferric derisomaltose) during dialysis bypasses hepcidin blockade. Target TSAT >20%, ferritin >100 ng/mL.
  3. Folate/B12: Dialytic loss replaced via IV/oral supplementation.
  4. Toxin Removal: High-flux/HDF enhances middle-molecule clearance (β2-microglobulin, indoxyl sulfate).
  5. Blood Conservation: Closed-circuit rinse-back, minimized lab draws, heparin titration.

Monitoring

Monthly Hb, quarterly iron studies, ESA dose adjustment per KDIGO guidelines (target Hb 10–11.5 g/dL). Avoid Hb >13 g/dL (stroke/thrombosis risk).

Kidney Disease - Related Articles